{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:11:37Z","timestamp":1790676697749,"version":"4.1.0"},"reference-count":36,"publisher":"European Respiratory Society (ERS)","issue":"5","license":[{"start":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T00:00:00Z","timestamp":1583366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.ersjournals.com\/user-licence"}],"funder":[{"DOI":"10.13039\/501100001203","name":"GlaxoSmithKline Australia","doi-asserted-by":"publisher","award":["Investigator Sponsored Studies grant"],"award-info":[{"award-number":["Investigator Sponsored Studies grant"]}],"id":[{"id":"10.13039\/501100001203","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2020,2,7]]},"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:p>Severe asthma is a high-burden disease. Real-world data on mepolizumab in patients with severe eosinophilic asthma is needed to assess whether the data from randomised controlled trials are applicable in a broader population.<\/jats:p>\n                  <jats:p>The Australian Mepolizumab Registry (AMR) was established with an aim to assess the use, effectiveness and safety of mepolizumab for severe eosinophilic asthma in Australia.<\/jats:p>\n                  <jats:p>\n                    Patients (n=309) with severe eosinophilic asthma (median age 60\u2005years, 58% female) commenced mepolizumab. They had poor symptom control (median Asthma Control Questionnaire (ACQ)-5 score of 3.4), frequent exacerbations (median three courses of oral corticosteroids (OCS) in the previous 12\u2005months), and 47% required daily OCS. Median baseline peripheral blood eosinophil level was 590\u2005cells\u00b7\u00b5L\n                    <jats:sup>\u22121<\/jats:sup>\n                    . Comorbidities were common: allergic rhinitis 63%, gastro-oesophageal reflux disease 52%, obesity 46%, nasal polyps 34%.\n                  <\/jats:p>\n                  <jats:p>Mepolizumab treatment reduced exacerbations requiring OCS compared with the previous year (annualised rate ratio 0.34 (95% CI 0.29\u20130.41); p&lt;0.001) and hospitalisations (rate ratio 0.46 (95% CI 0.33\u20130.63); p&lt;0.001). Treatment improved symptom control (median ACQ-5 reduced by 2.0 at 6\u2005months), quality of life and lung function. Higher blood eosinophil levels (p=0.003) and later age of asthma onset (p=0.028) predicted a better ACQ-5 response to mepolizumab, whilst being male (p=0.031) or having body mass index \u226530 (p=0.043) predicted a lesser response. Super-responders (upper 25% of ACQ-5 responders, n=61, 24%) had a higher T2 disease burden and fewer comorbidities at baseline.<\/jats:p>\n                  <jats:p>Mepolizumab therapy effectively reduces the significant and long-standing disease burden faced by patients with severe eosinophilic asthma in a real-world setting.<\/jats:p>","DOI":"10.1183\/13993003.02420-2019","type":"journal-article","created":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T08:25:15Z","timestamp":1583396715000},"page":"1902420","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":179,"title":["Mepolizumab effectiveness and identification of super-responders in severe asthma"],"prefix":"10.1183","volume":"55","author":[{"given":"Erin S.","family":"Harvey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Langton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Katelaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2489-227X","authenticated-orcid":false,"given":"Claude S.","family":"Farah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Gillman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Kritikos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naghmeh","family":"Radhakrishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Bardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul N.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Upham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Baraket","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Bowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Bowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li Ping","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Grainge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory P.","family":"Katsoulotos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa M.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6695-6350","authenticated-orcid":false,"given":"Helen K.","family":"Reddel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Rimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5676-6126","authenticated-orcid":false,"given":"Peter A.B.","family":"Wark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2020,3,5]]},"reference":[{"key":"2024102101233695000_55.5.1902420.1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2012.03981.x"},{"key":"2024102101233695000_55.5.1902420.2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00765-2017"},{"key":"2024102101233695000_55.5.1902420.3","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.jaci.2015.07.046","article-title":"Acute and chronic systemic corticosteroid-related complications in patients with severe asthma","volume":"136","author":"Lefebvre","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"2024102101233695000_55.5.1902420.4","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2015-207630"},{"key":"2024102101233695000_55.5.1902420.5","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/cea.13153","article-title":"Working while unwell: Workplace impairment in people with severe asthma","volume":"48","author":"Hiles","year":"2018","journal-title":"Clin Exp Allergy"},{"key":"2024102101233695000_55.5.1902420.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805435"},{"key":"2024102101233695000_55.5.1902420.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808991"},{"key":"2024102101233695000_55.5.1902420.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60988-X"},{"key":"2024102101233695000_55.5.1902420.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290"},{"key":"2024102101233695000_55.5.1902420.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403291"},{"key":"2024102101233695000_55.5.1902420.11","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2024102101233695000_55.5.1902420.12","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01444-2018"},{"key":"2024102101233695000_55.5.1902420.13","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.chest.2016.09.035","article-title":"Omalizumab treatment response in a population with severe allergic asthma and overlapping COPD","volume":"151","author":"Maltby","year":"2017","journal-title":"Chest"},{"key":"2024102101233695000_55.5.1902420.14","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/imj.13166","article-title":"Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry","volume":"46","author":"Gibson","year":"2016","journal-title":"Intern Med J"},{"key":"2024102101233695000_55.5.1902420.15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12890-018-0689-2","article-title":"Anti-IL-5 therapy in patients with severe eosinophilic asthma - clinical efficacy and possible criteria for treatment response","volume":"18","author":"Drick","year":"2018","journal-title":"BMC Pulm Med"},{"key":"2024102101233695000_55.5.1902420.16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.pupt.2018.12.003","article-title":"Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life","volume":"54","author":"Lombardi","year":"2019","journal-title":"Pulm Pharmacol Ther"},{"key":"2024102101233695000_55.5.1902420.17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pupt.2018.09.006","article-title":"Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study","volume":"53","author":"Pelaia","year":"2018","journal-title":"Pulm Pharmacol Ther"},{"key":"2024102101233695000_55.5.1902420.18","doi-asserted-by":"crossref","first-page":"101836","DOI":"10.1016\/j.pupt.2019.101836","article-title":"One year of mepolizumab. Efficacy and safety in real-life in Italy","volume":"58","author":"Bagnasco","year":"2019","journal-title":"Pulm Pharmacol Ther"},{"key":"2024102101233695000_55.5.1902420.19","doi-asserted-by":"crossref","unstructured":"Pertzov B , Unterman A , Shtraichman O , et al. Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma. J Asthma 2019: 1\u20136. doi:10.1080\/02770903.2019.1658208","DOI":"10.1080\/02770903.2019.1658208"},{"key":"2024102101233695000_55.5.1902420.20","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/17476348.2019.1676734","article-title":"Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response","volume":"13","author":"Caminati","year":"2019","journal-title":"Expert Rev Respir Med"},{"key":"2024102101233695000_55.5.1902420.21","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12890-019-0952-1","article-title":"Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis","volume":"19","author":"Numata","year":"2019","journal-title":"BMC Pulm Med"},{"key":"2024102101233695000_55.5.1902420.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2004.10.008"},{"key":"2024102101233695000_55.5.1902420.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2003.09.008"},{"key":"2024102101233695000_55.5.1902420.24","doi-asserted-by":"publisher","DOI":"10.1378\/chest.115.5.1265"},{"key":"2024102101233695000_55.5.1902420.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2005.08.012"},{"key":"2024102101233695000_55.5.1902420.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"2024102101233695000_55.5.1902420.27","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jaip.2016.12.030","article-title":"A Structured Approach to Specialist-referred Difficult Asthma Patients Improves Control of Comorbidities and Enhances Asthma Outcomes","volume":"5","author":"Tay","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024102101233695000_55.5.1902420.28","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2024102101233695000_55.5.1902420.29","doi-asserted-by":"crossref","first-page":"105806","DOI":"10.1016\/j.rmed.2019.105806","article-title":"Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma","volume":"159","author":"Albers","year":"2019","journal-title":"Respir Med"},{"key":"2024102101233695000_55.5.1902420.30","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200906-0896OC"},{"key":"2024102101233695000_55.5.1902420.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.10.006"},{"key":"2024102101233695000_55.5.1902420.32","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.pupt.2017.01.011","article-title":"Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils","volume":"43","author":"Brusselle","year":"2017","journal-title":"Pulm Pharmacol Ther"},{"key":"2024102101233695000_55.5.1902420.33","doi-asserted-by":"publisher","DOI":"10.1586\/17476348.2015.1000311"},{"key":"2024102101233695000_55.5.1902420.34","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200711-1754OC"},{"key":"2024102101233695000_55.5.1902420.35","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00100-2015"},{"key":"2024102101233695000_55.5.1902420.36","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaci.2018.09.033","article-title":"Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma","volume":"143","author":"Khatri","year":"2019","journal-title":"J Allergy Clin Immunol"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.02420-2019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T02:29:33Z","timestamp":1740364173000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.02420-2019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,5]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5,21]]},"published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1183\/13993003.02420-2019"],"URL":"https:\/\/doi.org\/10.1183\/13993003.02420-2019","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,5]]}}}